{
  "id": 7716017,
  "title": "Godavari Biorefineries jumps nearly 10% after Chinese patent grant for antiviral compound",
  "url": "https://urgent.news/2026/09/16/godavari-biorefineries-jumps-nearly-10-after-chinese-patent-grant-for",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T05:23:57.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/stock-markets/godavari-biorefineries-jumps-nearly-10-after-chinese-patent-grant-for-antiviral-compound/article71471170.ece"
  },
  "original_language": "en",
  "account": "Shares of Godavari Biorefineries Limited experienced a substantial increase of nearly 10% on Wednesday morning following the announcement of a patent grant from the Chinese Patent Office for an antiviral compound. The stock was trading at ₹248.66 as of 10:36 AM, marking a 9.72% rise from its previous close of ₹226.63. Throughout the trading session, the stock reached a high of ₹258.87 and a low of ₹224.00, which is also its 52-week low. With a traded volume of 22.27 lakh shares and a traded value of ₹56.06 crore, the company's market capitalization stood at ₹1,271.26 crore. China's National Intellectual Property Administration granted the patent on September 15, 2026. The patent, titled \"Use of Compounds for Treating Viral Infections,\" protects compounds that inhibit V-ATPase activity in cells and can be utilized in the production of antiviral drugs. Godavari Biorefineries is a constituent of the Nifty Sugar & Ethanol index and had declined by over 14% in the previous year before today's positive development.",
  "summary": "The patent, titled “Use of Compounds for Treating Viral Infections,” covers compounds that inhibit V-ATPase activity in cells, with applications in manufacturing antiviral medicaments",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}